Table 3.
Number and percentages of resistance of Campylobacter isolates from three batches.
| Antibiotic group | Antibiotic name | No. of resistant Campylobacter isolates (%) |
|||
|---|---|---|---|---|---|
| Batch 1 | Batch 2 | Batch 3 | Total | ||
| β-Lactams | AMP | 39/39 (100%) | 31/38 (81.6%) | 7/40 (17.5%) | 77/117 (65.8%) |
| AML | 39/39 (100%) | 31/38 (81.6%) | 7/40 (17.5%) | 77/117 (65.8%) | |
| CEX | 39/39 (100%) | 34/38 (89.5%) | 40/40 (100%) | 113/117 (96.6%) | |
| CRO | 39/39 (100%) | 20/38 (52.6%) | 40/40 (100%) | 99/117 (84.6%) | |
| Aminoglycosides | S | 39/39 (100%) | 31/38 (81.6%) | 40/40 (100%) | 109/117 (93.2%) |
| GEN | 39/39 (100%) | 5/38 (13.2%) | 6/40 (15.0%) | 50/117 (42.7%) | |
| K | 39/39 (100%) | 31/38 (81.6%) | 40/40 (100%) | 109/117 (93.2%) | |
| AMK | 39/39 (100%) | 2/38 (5.7%) | 2/40 (5.0%) | 42/117 (36.8%) | |
| TOB | 39/39 (100%) | 15/38 (39.5) | 40/40 (100%) | 94/117 (80.3%) | |
| Quinolones | NOR | 39/39 (100%) | 31/38 (81.6%) | 40/40 (100%) | 109/117 (93.2%) |
| CIP | 39/39 (100%) | 31/38 (81.6%) | 40/40 (100%) | 109/117 (93.2%) | |
| OFX | 39/39 (100%) | 31/38 (81.6%) | 40/40 (100%) | 109/117 (93.2%) | |
| NA | 39/39 (100%) | 31/38 (81.6%) | 40/40 (100%) | 109/117 (93.2%) | |
| ENR | 39/39 (100%) | 26/38 (68.4) | 40/40 (100%) | 105/117 (89.7%) | |
| Macrolide | E | 0 | 31/38 (81.6%) | 40/40 (100%) | 70/117 (59.8%) |
| AZM | 0 | 31/38 (81.6%) | 40/40 (100%) | 70/117 (59.8%) | |
| Tetracyclines | TE | 39/39 (100%) | 31/38 (81.6%) | 40/40 (100%) | 109/117 (93.2%) |
| Clindamycin | DA | 39/39 (100%) | 31/38 (81.6%) | 37/40 (92.5%) | 106/117 (90.6%) |